Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4790313 | 0.98 | NPSR1 (0.39) | NPSR1CYP1A2CYP2D6 | |
| SCHEMBL3909851 | 0.91 | NAAA (0.34) | NPSR1CYP1A2CYP2D6SIGMAR1 | |
| SCHEMBL6668505 | 0.86 | NPSR1 (0.31) | NPSR1 | |
| SCHEMBL10406934 | 0.80 | CYP1A2 (0.41) | CYP1A2CYP2D6 | |
| SCHEMBL988586 | 0.77 | NAAA (0.52) | NPSR1CYP1A2CYP2D6 | |
| SCHEMBL301678 | 0.76 | — | — | |
| SCHEMBL97249 | 0.76 | CYP1A2 (0.67) | NPSR1CYP1A2CYP2D6 | |
| Carbimide SCHEMBL8927383 | 0.74 | CYP1A2 (0.54) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL248532 | 0.74 | CYP1A2 (0.54) | CYP1A2CYP2D6 | |
| Ethane SCHEMBL8026831 | 0.74 | CYP1A2 (0.54) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146245-A1 | COMPOSITION FOR DIAGNOSING TUBERCULOSIS BY USING BIOMARKER, AND TUBERCULOSIS DIAGNOSTIC METHOD AND KIT USING SAME | 주식회사 더다봄 | 2023-08-03 | — | — | WO | disclosed |
| CN-108653728-B | Techniques for predicting, detecting, and reducing non-specific protein interference in assays involving immunoglobulin single variable domains | 埃博灵克斯股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-108663504-B | Techniques for predicting, detecting, and reducing non-specific protein interference in assays involving immunoglobulin single variable domains | ABLYNX N.V. (BE) | 2021-06-22 | — | — | CN | disclosed |
| US-10449261-B2 | Compositions targeting radiation-induced molecules and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2019-10-22 | — | — | US | disclosed |
| US-10226481-B2 | Pharmaceutical compositions composed of low molecular weight sulfated hyaluronan | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2688402-B1 | MEANS FOR TREATING OR PREVENTING UROLOGICAL INFLAMMATION | UNIV UTAH RES FOUND (US) | 2018-10-24 | — | — | EP | disclosed |
| CN-108659120-A | Technology for predicting, detecting and reducing the nonspecific proteins being related in the measuring method of immunoglobulin (Ig) list variable domains interference | 埃博灵克斯股份有限公司 | 2018-10-16 | — | — | CN | disclosed |
| CN-108653728-A | Technology for predicting, detecting and reducing the nonspecific proteins being related in the measuring method of immunoglobulin (Ig) list variable domains interference | 埃博灵克斯股份有限公司 | 2018-10-16 | — | — | CN | disclosed |
| CN-108659121-A | Technology for predicting, detecting and reducing the nonspecific proteins being related in the measuring method of immunoglobulin (Ig) list variable domains interference | 埃博灵克斯股份有限公司 | 2018-10-16 | — | — | CN | disclosed |
| CN-108663504-A | Techniques for predicting, detecting, and reducing non-specific protein interference in assays involving immunoglobulin single variable domains | 埃博灵克斯股份有限公司 | 2018-10-16 | — | — | CN | disclosed |
| WO-2002014261-A2 | 4-SUBSTITUTED D-GLUTAMIC ACID DERIVATIVES FOR USE AS ANTIBIOTIC | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| US-5831012-A | HEAT STABLITY, MUTAGENESIS | PHARMACIA & UPJOHN AKTIEBOLAG (SE) | 1998-11-03 | — | — | US | disclosed |
| EP-0777497-A4 | HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS | SCRIPPS RESEARCH INST (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0586537-A4 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO INC (US) | 1997-06-25 | — | — | EP | disclosed |
| EP-0777497-A1 | HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996002273-A9 | HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS | — | 1996-04-04 | — | — | WO | disclosed |
| WO-1996002273-A1 | HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0586537-A1 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO. INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1989004672-A1 | DERIVATIVES OF LINCOSAMINIDE ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1989-06-01 | — | — | WO | disclosed |
| US-4293557-A | AMIDES | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1981-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10449261-B2 | Compositions targeting radiation-induced molecules and methods of use thereof | HSP90B1, HSPBP1, HSP90AB1 | NPSR1 1663/4885CYP1A2 4832/4885CYP2D6 4783/4885 |
| US-10226481-B2 | Pharmaceutical compositions composed of low molecular weight sulfated hyaluronan | CD44, HPSE, CSGALNACT1 | NPSR1 334/4885CYP1A2 3301/4885CYP2D6 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.